Myriad Genetics Inc (MYGN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Myriad Genetics Inc stock (MYGN) is currently trading at $4.68. Myriad Genetics Inc PS ratio (Price-to-Sales) is 0.53. Analyst consensus price target for MYGN is $7.78. WallStSmart rates MYGN as Sell.
- MYGN PE ratio analysis and historical PE chart
- MYGN PS ratio (Price-to-Sales) history and trend
- MYGN intrinsic value — DCF, Graham Number, EPV models
- MYGN stock price prediction 2025 2026 2027 2028 2029 2030
- MYGN fair value vs current price
- MYGN insider transactions and insider buying
- Is MYGN undervalued or overvalued?
- Myriad Genetics Inc financial analysis — revenue, earnings, cash flow
- MYGN Piotroski F-Score and Altman Z-Score
- MYGN analyst price target and Smart Rating
Myriad Genetics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Myriad Genetics Inc (MYGN) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/sales, price/book. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Myriad Genetics Inc (MYGN) Key Strengths (4)
Paying less than $1 for every $1 of annual revenue
103.89% of shares held by major funds and institutions
Good growth relative to its price
Trading at 1.17x book value, attractively priced
Supporting Valuation Data
Myriad Genetics Inc (MYGN) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -0.40%, a shrinking business
Company is losing money with a negative profit margin
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Myriad Genetics Inc (MYGN) Detailed Analysis Report
Overall Assessment
This company scores 42/100 in our Smart Analysis, earning a D grade. Out of 9 metrics analyzed, 4 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Institutional Own., PEG Ratio. Valuation metrics including PEG Ratio (1.40), Price/Sales (0.53), Price/Book (1.17) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Growth concerns include Revenue Growth at -0.40%, which may limit upside. Profitability pressure is visible in Return on Equity at -68.40%, Operating Margin at -1.43%, Profit Margin at -44.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -68.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -0.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MYGN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MYGN's Price-to-Sales ratio of 0.53x trades at a deep discount to its historical average of 10.98x (1th percentile). The current valuation is 99% below its historical high of 42.74x set in Oct 2007, and 2% above its historical low of 0.52x in Mar 2026.
Compare MYGN with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Myriad Genetics Inc (MYGN) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Myriad Genetics Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 825M with 0% growth year-over-year. The company is currently unprofitable, posting a -44.4% profit margin.
Key Findings
Generating 5M in free cash flow and 11M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -44.4% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Volatility is elevated with a beta of 1.93, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Myriad Genetics Inc.
Bottom Line
Myriad Genetics Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(41 last 3 months)
| Insider | Type | Shares |
|---|---|---|
RAHA, SAMRAAT S. Director, President and CEO | Buy | +40,000 |
| Insider | Type | Shares |
|---|---|---|
SOLAIMAN, SHEREEN Chief People Officer | Sell | -1,675 |
| Insider | Type | Shares |
|---|---|---|
PHANSTIEL, S. LOUISE Director | Buy | +48,000 |
| Insider | Type | Shares |
|---|---|---|
PHANSTIEL, S. LOUISE Director | Buy | +50,407 |
| Insider | Type | Shares |
|---|---|---|
PHANSTIEL, S. LOUISE Director | Buy | +6,100 |
| Insider | Type | Shares |
|---|---|---|
MUZZEY, DALE Chief Scientific Officer | Sell | -418 |
Data sourced from SEC Form 4 filings
Last updated: 10:12:18 AM
About Myriad Genetics Inc(MYGN)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.